ODI Pharma AB (“ODI” or the “Company”) announces today that the Company has received approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) in Poland for its Marketing Authorization Holder (MAH) application. The approval means that ODI has the right to distribute and sell its medical cannabis products on the Polish market.
The approved Marketing Authorization Holder application is an important milestone and has meant 3 years of intensive work for the Company as it is required to proceed with the work to start selling the products on the Polish medical market. The Company will now proceed with the necessary steps to bring the products to the Polish market as soon as possible, through its subsidiary ODI Pharma Polska Sp. z o.o.
“We are very pleased that our intensive work over the last few years has now paid off and are proud of the critical steps we have taken to receive the approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. We now look forward to the next steps for Project Poland.” - says Derek Simmross, CEO.
For more information on ODI Pharma, please contact:
Derek Simmross, CEO, ODI Pharma AB
E-mail: info@odipharma.com
This information is information that ODI Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above on 24 January 2023.
ODI Pharma AB
ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis and cosmetics products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.
